Search Results

There are 6531 results for: content related to: Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice

  1. Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 49, Issue 6, June 2009, Pages: 700–709, Dr Timothy Eley, Dr Feng R. Luo, Dr Shruti Agrawal, Dr Ashish Sanil, Dr James Manning, Dr Tong Li, Dr Anne Blackwood-Chirchir and Dr Richard Bertz

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009333854

  2. Pharmacogenomics of Dasatinib (Sprycel™)

    Kinase Inhibitor Drugs

    Fei Huang, Edwin A. Clark, Pages: 365–402, 2009

    Published Online : 28 SEP 2009, DOI: 10.1002/9780470524961.ch15

  3. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model

    The Journal of Pathology

    Volume 230, Issue 4, August 2013, Pages: 430–440, Saadia A Karim, Helen Creedon, Hitesh Patel, Neil O Carragher, Jennifer P Morton, William J Muller, Thomas RJ Evans, Barry Gusterson, Owen J Sansom and Valerie G Brunton

    Article first published online : 9 JUL 2013, DOI: 10.1002/path.4202

  4. You have free access to this content
    Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

    International Journal of Cancer

    Volume 131, Issue 6, 15 September 2012, Pages: E916–E927, Nicole Hassold, Katharina Seystahl, Kristina Kempf, Doris Urlaub, Michael Zekl, Hermann Einsele, Carsten Watzl, Jörg Wischhusen and Ruth Seggewiss-Bernhardt

    Article first published online : 4 APR 2012, DOI: 10.1002/ijc.27537

  5. You have free access to this content
    Dasatinib induces autophagic cell death in human ovarian cancer


    Volume 116, Issue 21, 1 November 2010, Pages: 4980–4990, Xiao-Feng Le, Weiqun Mao, Zhen Lu, Bing Z. Carter and Robert C. Bast Jr

    Article first published online : 13 JUL 2010, DOI: 10.1002/cncr.25426

  6. Fluorescent Visualization of Src by Using Dasatinib-BODIPY


    Volume 15, Issue 9, June 16, 2014, Pages: 1317–1324, Dr. Michael L. Vetter, Dr. Zijuan Zhang, Dr. Shuai Liu, Dr. Jinhua Wang, HaeYeon Cho, Dr. Jianming Zhang, Prof. Wei Zhang, Prof. Nathanael S. Gray and Prof. Priscilla L. Yang

    Article first published online : 14 MAY 2014, DOI: 10.1002/cbic.201402010

  7. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera

    European Journal of Clinical Investigation

    Volume 38, Issue 8, August 2008, Pages: 578–584, M. Wappl, E. Jaeger, B. Streubel, H. Gisslinger, I. Schwarzinger, P. Valent and L. Oehler

    Article first published online : 17 JUL 2008, DOI: 10.1111/j.1365-2362.2008.01982.x

  8. Ingredients in Fruit Juices Interact with Dasatinib Through Inhibition of BCRP: A New Mechanism of Beverage–Drug Interaction

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 1, January 2015, Pages: 266–275, Brett Fleisher, Jesse Unum, Jie Shao and Guohua An

    Article first published online : 21 NOV 2014, DOI: 10.1002/jps.24289

  9. You have free access to this content
    Practical management of patients with chronic myeloid leukemia


    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Article first published online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  10. Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia

    The Journal of Clinical Pharmacology

    Volume 48, Issue 11, November 2008, Pages: 1254–1269, Guowei Dai, Marc Pfister, Anne Blackwood-Chirchir and Amit Roy

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008320604

  11. You have free access to this content
    Dasatinib combined with docetaxel for castration-resistant prostate cancer


    Volume 118, Issue 1, 1 January 2012, Pages: 63–71, John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal and Christopher J. Logothetis

    Article first published online : 4 MAR 2011, DOI: 10.1002/cncr.26204

  12. You have free access to this content
    Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals

    British Journal of Haematology

    Volume 153, Issue 2, April 2011, Pages: 199–211, Alison M. MCCaig, Emilio Cosimo, Michael T. Leach and Alison M. Michie

    Article first published online : 24 FEB 2011, DOI: 10.1111/j.1365-2141.2010.08507.x

  13. You have free access to this content
    Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors


    Volume 116, Issue 6, 15 March 2010, Pages: 1582–1591, Faye M. Johnson, Shruti Agrawal, Howard Burris, Lee Rosen, Navneet Dhillon, David Hong, Anne Blackwood-Chirchir, Feng R. Luo, Oumar Sy, Sanjeev Kaul and Alberto A. Chiappori

    Article first published online : 27 JAN 2010, DOI: 10.1002/cncr.24927

  14. Dasatinib in chronic myeloid leukemia: A limited Indian experience

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 4, December 2012, Pages: 375–379, Atul SHARMA, Ankur BAHL, Vinod RAINA, Lalit KUMAR and Ritu GUPTA

    Article first published online : 6 JUL 2012, DOI: 10.1111/j.1743-7563.2012.01557.x

  15. You have full text access to this OnlineOpen article
    Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

    European Journal of Haematology

    Volume 94, Issue 3, March 2015, Pages: 243–250, Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, Arta Dreimane, Hans Ehrencrona, Tobias Gedde-Dahl, Bjørn Tore Gjertsen, Martin Höglund, Perttu Koskenvesa, Kourosh Lotfi, Waleed Majeed, Berit Markevärn, Lotta Ohm, Ulla Olsson-Strömberg, Kari Remes, Merja Suominen, Bengt Simonsson, Kimmo Porkka, Satu Mustjoki, Johan Richter and for the Nordic CML Study Group (NCMLSG)

    Article first published online : 13 SEP 2014, DOI: 10.1111/ejh.12423

  16. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

    European Journal of Clinical Investigation

    Volume 39, Issue 12, December 2009, Pages: 1098–1109, C. Sillaber, H. Herrmann, K. Bennett, U. Rix, C. Baumgartner, A. Böhm, S. Herndlhofer, E. Tschachler, G. Superti-Furga, U. Jäger and P. Valent

    Article first published online : 9 SEP 2009, DOI: 10.1111/j.1365-2362.2009.02206.x

  17. You have free access to this content
    Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model

    International Journal of Cancer

    Volume 125, Issue 11, 1 December 2009, Pages: 2547–2555, Roberta Vitali, Camillo Mancini, Vincenzo Cesi, Barbara Tanno, Marta Piscitelli, Mariateresa Mancuso, Fabiola Sesti, Emanuela Pasquali, Bruno Calabretta, Carlo Dominici and Giuseppe Raschellà

    Article first published online : 28 MAY 2009, DOI: 10.1002/ijc.24606

  18. You have free access to this content
    The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

    Journal of Bone and Mineral Research

    Volume 25, Issue 8, August 2010, Pages: 1759–1770, Kate Vandyke, Andrea L Dewar, Peter Diamond, Stephen Fitter, Christopher G Schultz, Natalie A Sims and Andrew CW Zannettino

    Article first published online : 11 MAR 2010, DOI: 10.1002/jbmr.85

  19. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

    Hematological Oncology

    Volume 31, Issue 3, September 2013, Pages: 156–163, Takayoshi Uchiyama, Naoya Sato, Miwako Narita, Akie Yamahira, Minami Iwabuchi, Tatsuo Furukawa, Hirohito Sone and Masuhiro Takahashi

    Article first published online : 29 OCT 2012, DOI: 10.1002/hon.2034

  20. You have free access to this content
    Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro


    Volume 57, Issue 5, May 2013, Pages: 1838–1846, Richard S. Finn, Alexey Aleshin, Judy Dering, Peter Yang, Charles Ginther, Amrita Desai, Danyun Zhao, Erika von Euw, Ronald W. Busuttil and Dennis J. Slamon

    Article first published online : 1 APR 2013, DOI: 10.1002/hep.26223